ACRS (STOCKS)
Aclaris Therapeutics, Inc.
$3.919100
-0.120900 (-2.99%)
Prev close: $4.040000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Neal S. Walker
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $470.32M
- Employees
- 64
- P/E (TTM)
- -7.63
- P/B (TTM)
- 4.72
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.16 | $-0.15 | -0.0070 | -4.58% |
|
Sep 2025 (Q3)
|
$-0.12 | $-0.14 | +0.0177 | +12.85% |
|
Jun 2025 (Q2)
|
$-0.13 | $-0.14 | +0.0055 | +4.06% |
|
Mar 2025 (Q1)
|
$-0.12 | $-0.12 | -0.0001 | -0.08% |
Financial Statements
| Revenues | $7.83M |
| Benefits Costs and Expenses | $72.75M |
| Cost Of Revenue | $2.09M |
| Costs And Expenses | $84.20M |
| Gross Profit | $5.74M |
| Nonoperating Income/Loss | $11.45M |
| Operating Expenses | $82.11M |
| Research and Development | $52.65M |
| Other Operating Expenses | $29.47M |
| Operating Income/Loss | -$76.38M |
| Income/Loss From Continuing Operations After Tax | -$64.92M |
| Income/Loss From Continuing Operations Before Tax | -$64.92M |
| Net Income/Loss | -$64.92M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$64.92M |
| Net Income/Loss Available To Common Stockholders, Basic | -$64.92M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.53 |
| Diluted Earnings Per Share | -$0.53 |
| Basic Average Shares | 122,564,741 |
| Diluted Average Shares | 122,564,741 |
| Assets | $160.46M |
| Current Assets | $96.32M |
| Cash | $151.40M |
| Noncurrent Assets | $64.14M |
| Fixed Assets | $761.00K |
| Other Non-current Assets | $63.38M |
| Liabilities | $57.38M |
| Current Liabilities | $28.65M |
| Accounts Payable | $13.16M |
| Wages | $5.30M |
| Other Current Liabilities | $10.19M |
| Noncurrent Liabilities | $28.73M |
| Equity | $103.08M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $103.08M |
| Liabilities And Equity | $160.46M |
| Net Cash Flow From Operating Activities | -$47.11M |
| Net Cash Flow From Operating Activities, Continuing | -$47.11M |
| Net Cash Flow From Investing Activities | $48.37M |
| Net Cash Flow From Investing Activities, Continuing | $48.37M |
| Net Cash Flow From Financing Activities | -$5.86M |
| Net Cash Flow From Financing Activities, Continuing | -$5.86M |
| Net Cash Flow | -$4.61M |
| Net Cash Flow, Continuing | -$4.61M |
| Comprehensive Income/Loss | -$64.41M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$64.41M |
| Other Comprehensive Income/Loss | $513.00K |